A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Slides:

Advertisements

Similar presentations

FRISC II: Fragmin and fast Revascularization during InStability in Coronary artery disease - LONG-TERM HEPARIN - Purpose To assess efficacy of long-term.

Advertisements

Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

1Coiffier B et al. Proc ASH 2010;Abstract 114.

Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.

Presented By Raymond Huang at 2014 ASCO Annual Meeting

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Dr Marco Matos Medical Oncologist Gold Coast Cancer Care, Gold Coast University Hospital and, Pacific Private Oncology Group.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Presented By Michael Overman at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory.

: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

A cura di Filippo de Marinis

Shustov AR et al. Proc ASH 2010;Abstract 961.

Presented By Michael Lee at 2016 ASCO Annual Meeting

Highlights: Myeloma Oral Session

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Martinelli G et al. Proc ASH 2015;Abstract 679.

Fujiwara H et al. Proc ASH 2015;Abstract 181.

Presented By Amrita Krishnan at 2016 ASCO Annual Meeting

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Updates and Perspectives in Diabetic Dyslipidemia

Peripheral T-Cell Lymphoma in 2013

Metastatic Renal Cell Carcinoma

Efficacy and Safety of Edoxaban in Patients With AF and HF

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Faderl S et al. Proc ASCO 2011;Abstract 6503.

Personalized Therapy in Relapsed or Refractory CLL

Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Advani RH et al. Proc ASH 2011;Abstract 443.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Macroscopic observations of the mogamulizumab-induced skin-related AEs

Presentation transcript:

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Adult T-cell Leukemia-Lymphoma (ATL) Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Adult T-cell Leukemia-Lymphoma (ATL) Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Aggressive Subtypes of ATL have a Poor Prognosis Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Treatment of ATL Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Slide 5 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Slide 6 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Slide 7 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Slide 8 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Efficacy Assessments Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Select Demographic Data Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Results: Overall Response Rate Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Summary of TEAEs (>20% in the Mogamulizumab Arm) by Treatment Arm (Safety Analysis Set) Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Study Summary Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Conclusions Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Investigators and Study Sites Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Acknowledgements Presented By Adrienne Phillips at 2016 ASCO Annual Meeting